Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…Abstract Number: 2238 • ACR Convergence 2024
The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…Abstract Number: 2380 • ACR Convergence 2024
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…Abstract Number: 0052 • ACR Convergence 2024
Single Cell RNA-sequencing Analysis Revealed Peripheral Blood and Synovial Alterations of Dendritic Cells in Rheumatoid Arthritis
Background/Purpose: Recent single cell analyses have unveiled novel dendritic cell (DC) subpopulations that could potentially be linked to rheumatoid arthritis (RA). This study aimed to…Abstract Number: 0506 • ACR Convergence 2024
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…Abstract Number: 0601 • ACR Convergence 2024
Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…Abstract Number: 0828 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…Abstract Number: 1293 • ACR Convergence 2024
Educational Quality Improvement (QI) Project to Improve Inpatient Purine Restricted Diet Order Placement for Patients Admitted with Gout Flares
Background/Purpose: Gout is a chronic, but treatable, inflammatory disease characterized by intermittent flares involving the deposition of monosodium urate crystals in and around joints. It…Abstract Number: 1367 • ACR Convergence 2024
Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…Abstract Number: 1875 • ACR Convergence 2024
Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
Background/Purpose: Acute exposure to air pollution has been associated with flares of psoriasis and chronic inflammatory arthritides in prior studies. However, the impact of air pollution,…Abstract Number: 2241 • ACR Convergence 2024
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…Abstract Number: 2390 • ACR Convergence 2024
Anti-Sm Antibody Titers Vary During SLE Disease Course
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by positive antibodies to dsDNA and/or Sm which have high specificity for the disease. While anti-dsDNA titers are…Abstract Number: 0103 • ACR Convergence 2024
CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome
Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…Abstract Number: 0510 • ACR Convergence 2024
Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis
Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 102
- Next Page »